Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ImmuCell Corp (ICCC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$10.37+1.17%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ICCC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Expand First Defense production capacity | The company is expanding production for its First Defense product. | Intact | Failure to convert facilities for First Defense by mid-2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ICCC is a smaller-cap growth business with a seasonal revenue pattern and meaningful execution risk. Its multi-year view is intact: recent performance remains strong, while management is investing to expand production capacity.
The valuation evidence is mixed and low confidence: one measure points to ICCC as cheap versus peers, while another shows a 35% premium. The expectations gap is modest, and the priced-in assessment flags valuation alone as expensive, not a broader combination of weak fundamentals and turbulence.
Near term, product sales growth has been positive, though it varied across recent quarters, and revenue moderated after peak season as management expected. Capacity expansion is underway, with one phase expected to be completed in the first half of 2027. The next earnings report carries elevated miss risk, and any guidance cut would be a meaningful negative.
The multi-year thesis hinges on continued product sales growth and successful expansion of First Defense production capacity. Near term, weaker jobs data could raise recession concerns for cyclical names, while strong results and guidance from healthcare bellwethers could support sector momentum. The evidence on these forward scenarios is limited and conditional.
For the 1-3 year view, strong recent performance and active capacity investment support an intact thesis, but valuation signals conflict and near-term execution risk is high. The key test is whether sales growth and guidance remain sound as seasonal effects and capacity plans play out. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in ImmuCell Corp's published investment case. The stated target is Stable leadership and clear execution through 2026. |
| Intact |
| Further key management departures or execution failures in 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth after backorder clearance | ImmuCell is growing sales after clearing a big backorder. | Broken | YoY revenue growth falls below 13.9% in FY26 | Revenue growth: 11.5% FY2026-Q2; GAAP. Published target: >=13.9% YoY revenue growth. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 202611.501114 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.11 → $-0.11 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-07-25 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-07-26 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-07-27 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-07-28 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-07-29 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-07-30 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-07-31 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-01 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-02 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-03 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-04 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-05 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-06 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-07 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-08 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-09 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-10 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-12 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-13 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-14 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-15 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-16 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-17 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-18 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-19 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-20 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-21 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-22 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-23 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-24 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-25 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-26 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-27 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-28 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-29 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-30 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-08-31 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-01 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-02 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-03 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-04 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-05 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-06 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-07 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-08 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-09 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-10 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-11 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-12 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-13 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-14 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-15 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-16 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-17 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-18 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-19 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-20 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-21 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-22 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-23 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-24 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-25 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-26 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-27 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-28 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-29 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-09-30 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-01 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-02 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-03 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-04 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-05 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-06 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-07 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-08 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-09 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-10 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-11 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-12 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-13 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-14 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-15 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-16 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-17 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-18 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-19 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-20 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-21 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-22 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-23 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-24 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-25 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-26 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-27 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-28 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-29 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-30 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-10-31 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-11-01 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-11-02 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-11-03 | $-0.11 | $19,200,000 | 1 / 1 |
| 2026-11-04 | $-0.11 | $19,200,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.